Content by Keyword: Drug Therapy

Basic report
Drug Use and Spending for Medicare Beneficiaries

Drug Use and Spending for Medicare Beneficiaries During Part A Qualifying Skilled Nursing Facility Stays and Non-Qualifying Long-Term Care Facility Stays

U.S. Department of Health and Human Services Drug Use and Spending for Medicare Beneficiaries During Part A Qualifying Skilled Nursing Facility Stays and Non-Qualifying Long-Term Care Facility Stays Bruce Stuart, PhD, Linda Simoni-Wastila, RPh, PhD and Thomas Shaffer, MHS University of Maryland, Baltimore, Peter Lamy Center on
  • druguse.pdf
    export-csvPDF
Basic report
Report on the Effects of Regulation on Quality of

Report on the Effects of Regulation on Quality of Care: Analysis of the Effect of Regulation on the Quality of Care in Board and Care Homes

U.S. Department of Health and Human Services Report on the Effects of Regulation on Quality of Care: Analysis of the Effect of Regulation on the Quality of Care in Board and Care Homes Charles Phillips, Linda Lux, Judith Wildfire, Angela Greene, Catherine Hawes, George Dunteman, Vince Iannacchione, Vincent Mor, Rebecca Green and
  • b&crpt.pdf
    export-csvPDF
Prescription Drug Spending by Medicare

Prescription Drug Spending by Medicare Beneficiaries in Institutional and Residential Settings, 1998-2001

U.S. Department of Health and Human Services
Report page
Acknowledgments

A Description of Board and Care Facilities, Operators, and Residents. Acknowledgments

Drug data entry and related analyses were funded by a grant from the Geriatric Drug Therapy Research Institute to Brown University. Diana Spore was supported by the Agency for Health Care Policy and Research Training Grant T32-HS00011 awarded to Brown University.
Basic report
Subacute Care: Review of the Literature

Subacute Care: Review of the Literature

Lewin-VHI, Inc.
  • scltrves.pdf
    export-csvPDF
Report page
4.5.2 Safety Reporting Requirements for

Examination of Clinical Trial Costs and Barriers for Drug Development. 4.5.2 Safety Reporting Requirements for Investigational New Drugs (INDs) and Biologics (21 CFR 312)

In the course of clinical investigations conducted under investigational new drug (IND) applications, information regarding adverse events must be communicated among investigators, sponsors, IRBs, and FDA in safety reports. There are a number of terms that are used to categorize adverse events and thereby determine which must be reported. The most
Report page
A.5.2 Current Treatment

Analytical Framework for Examining the Value of Antibacterial Products. A.5.2 Current Treatment

Treatment often involves empiric broad-spectrum antibacterial drug therapy, initially. Modifications of the antibacterial drug regimen can be made after urine culture and sensitivity analysis results are obtained. Mild to moderately ill patients may be treated in an outpatient setting with oral antibacterial drugs, such as norfloxacin or ciproflox
Report page
5 Rapid Point-of-Care (POC) Diagnostics

Analytical Framework for Examining the Value of Antibacterial Products. 5 Rapid Point-of-Care (POC) Diagnostics

There is a need for specific and inexpensive rapid point of care (POC) diagnostic tests that can be used for clinical management of infectious diseases.  Diagnostics are important as they allow tailoring treatment with antibacterial drugs, reducing unnecessary antibacterial drug use and thereby delaying the development of antibacterial resistance
Report page
3.6.5.1 ABOM

Analytical Framework for Examining the Value of Antibacterial Products. 3.6.5.1 Abom

Total Number of Cases that do not Result in Death
Report page
Medicare Modernization Act of 2003 Improvements

Diabetes: A National Plan for Action. Medicare Modernization Act of 2003 Improvements for Individuals with Diabetes

The new law enhances diabetes coverage for beneficiaries by adding several improvements.
Report page
How Does the Medicare Replacement Drug

Performance Improvement 2008. How Does the Medicare Replacement Drug Demonstration Affect Patient Access to Care, Health Outcomes, and Medicare Cost-Effectiveness?

The study examined the impact of the Medicare Replacement Drug Demonstration on patient access to care and patient outcomes, and analyzed its impact on Medicare spending, detailing cost savings to Medicare due to reduced physicians´ services and hospital outpatient department services for administration of replaced drugs. Over 42,000 Medicare ben
Report page
Goal 1 - IMPROVE THE SAFETY, QUALITY,

Performance Improvement 2008. Goal 1 - Improve the Safety, Quality, Affordability and Accessibility of Health CARE Including Behavioral Health CARE and Long Term CARE

IMPROVE THE SAFETY, QUALITY, AFFORDABILITY AND ACCESSIBILITY OF HEALTH CARE INCLUDING BEHAVIORAL HEALTH CARE AND LONG TERM CARE This Strategic Goal targets the need for people to be able to obtain and maintain affordable health care coverage, receive efficient high-quality health care services, and access appropriate information for informed
Report page
The Role of Home and Community-Based

Performance Improvement 1999. The Role of Home and Community-Based Services in Meeting the Health Care Needs of People with HIV/AIDS

Highlights
Report page
Health Care Financing Administration

Performance Improvement 1998. Health Care Financing Administration

Contents Limited-Service Hospital Pioneers: Challenges and Successes of the Essential Access Community Hospital/Rural Primary Care Hospital (EACH-RPCH) Program and Medical Assistance Facility (MAF) Demonstration Comparative Study of the Use of EPSDT and Other Preventive and Curative Health Care Services by Children Enroll
Report page
Agency for Health Care Policy and Research

Performance Improvement 1998. Agency for Health Care Policy and Research

Contents Publications of the Patient Outcomes Research Teams (PORTS), May 1996 and Medical Treatment Effectiveness Projects 1989 through 1995 Final Report on Changes Needed in CONQUEST's Software Based Programs Final Report on Changes Needed in CONQUEST 1.0's Structure and Classification Scheme Assessment of the
Report page
Health Care Financing Administration

Performance Improvement 1998. Health Care Financing Administration

MISSION: To promote the timely delivery of appropriate, quality health care to the Nation's aged, disabled, and poor through administration of the Medicare and Medicaid programs. Evaluation Program
Report page
Market Barriers to the Development of

Performance Improvement 1998. Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report

Highlights
Report page
Executive Summary

Performance Improvement 1998. Executive Summary

Performance Improvement 1998 is the third annual report of the U.S. Department of Health and Human Services (HHS) on its evaluation activities. As a report to Congress, it summarizes the findings of HHS evaluations completed in fiscal year (FY) 1997. In that year, HHS agencies produced 155 evaluation reports and supported more than 335
Report
Performance Improvement 1998

Performance Improvement 1998

Performance Improvement 1998 is the third annual report of the U.S. Department of Health and Human Services (HHS) on its evaluation activities. As a report to Congress, it summarizes the findings of HHS evaluations completed in fiscal year (FY) 1997. In that year, HHS agencies produced 155 evaluation reports and supported more than 335 evaluation
Report page
IMPACT OF PRESCRIPTION DRUG COVERAGE ON MEDICARE

Performance Improvement 2005. Impact of Prescription Drug Coverage on Medicare Program Expenditures - a Case Study of the Evaluation of the Umwa

This report addressed how prescription coverage influenced the use of medical care when drug therapy substituted for or complemented other medical services. The research had three specific aims: (1) To examine the impact of drug coverage on drug expenditures and other expenditures covered by the Medicare program from 1995 to the latest available d

Pages